Home News Dupilumab long-term data show sustained improvement in moderate to severe asthma back to News
minute read
Long-term treatment with dupilumab shows sustained improvement in lung function and reduction in severe exacerbations in patients with moderate to severe asthma, according to new results from a phase 3, open-label extension trial.
Topics: Press Coverage
13001 East 17th Place
Aurora, CO 80045
303.724.5375
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
